On the molecular level, overexpression of the ERCC1 and upregulation of CTR1 gene were observed, both mutations being indicative of cisplatin resistance: platinum-based drugs are predominantly linked to and eradicate cancer cells with negative ERCC1 expression, and the expression of the copper transporter receptor 1 (CTR1) is correlated with intratumoral platinum accumulation, with increased expression being indicative of poor uptake. The gene discussed is ERCC1; the disease is cancer.